<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Bronchiectasis in children without cystic fibrosis: Management</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Bronchiectasis in children without cystic fibrosis: Management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Bronchiectasis in children without cystic fibrosis: Management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Vikas Goyal, MBBS, DCH, FRACP, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anne B Chang, MBBS, FRACP, PhD, FAPSR, FAHMS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">George B Mallory, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 12, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Bronchiectasis in children is defined as the presence of abnormal bronchial dilatation on chest computed tomography scans, in combination with a clinical syndrome of recurrent or persistent wet/productive cough, airway infection, and/or inflammation infections [<a href="#rid1">1-3</a>]. Although cystic fibrosis (CF) is the most common cause of pediatric bronchiectasis in resource-abundant settings, other causes predominate worldwide. Pediatric bronchiectasis unrelated to CF remains underrecognized, undertreated, and underserviced [<a href="#rid4">4,5</a>].</p><p>Management of bronchiectasis in children without CF is discussed below. This includes children with bronchiectasis related to underlying diseases such as primary ciliary dyskinesia and immunodeficiency. However, when underlying causes are identified, additional therapies are usually indicated. Other aspects of bronchiectasis in this population are discussed separately. (See  <a class="medical medical_review" href="/d/html/6358.html" rel="external">"Bronchiectasis in children: Pathophysiology and causes"</a> and  <a class="medical medical_review" href="/d/html/6360.html" rel="external">"Bronchiectasis in children: Clinical manifestations and evaluation"</a> and  <a class="medical medical_review" href="/d/html/4338.html" rel="external">"Primary ciliary dyskinesia (immotile-cilia syndrome)"</a>.)</p><p>The management of CF-related bronchiectasis is discussed in detail in separate topic reviews. (See  <a class="medical medical_review" href="/d/html/6372.html" rel="external">"Cystic fibrosis: Overview of the treatment of lung disease"</a> and  <a class="medical medical_review" href="/d/html/6371.html" rel="external">"Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection"</a> and  <a class="medical medical_review" href="/d/html/110933.html" rel="external">"Cystic fibrosis: Management of pulmonary exacerbations"</a> and  <a class="medical medical_review" href="/d/html/129117.html" rel="external">"Cystic fibrosis: Management of advanced lung disease"</a>.)</p><p class="headingAnchor" id="H1447343889"><span class="h1">OVERVIEW</span><span class="headingEndMark"> — </span>Optimal clinical care for children with bronchiectasis improves clinical outcomes. For those with mild disease, optimal care can halt the progression and sometimes even reverse the disease [<a href="#rid3">3,6</a>]. Unfortunately, children with bronchiectasis unrelated to cystic fibrosis (CF) often have poorer access to multidisciplinary clinics and resultant poorer lung function outcomes compared with children with CF [<a href="#rid5">5</a>]. Also, they have a worse outcome in growth and their parents experience more stress and anxiety compared with children with CF [<a href="#rid7">7</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aged-based care</strong> – Bronchiectasis care for children differs from that for adults in several ways:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Care must be tailored to the child's age and understanding, and education and support includes the parents or other caregivers.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Diagnostic and treatment methods, such as airway clearance techniques, may differ according to age.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Therapeutic choices may differ because of the biologic differences between pediatric and adult bronchiectasis, which include altered pathogen profiles (bacteria [<a href="#rid8">8</a>] and microbiota [<a href="#rid9">9</a>]), age-related immunologic responses [<a href="#rid10">10</a>], and treatment outcomes [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Comorbidities and underlying etiologies are substantially different between adults and children [<a href="#rid11">11</a>]. (See  <a class="medical medical_review" href="/d/html/6360.html" rel="external">"Bronchiectasis in children: Clinical manifestations and evaluation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Components of management</strong> – Bronchiectasis is best managed in a multidisciplinary clinic. Treatment and long-term management are aimed at curtailing the cycle of infection and inflammation. In contrast with adults with bronchiectasis, clinicians should be cognizant that upon diagnosing bronchiectasis in children, their lung function can be preserved in the long term and even improve [<a href="#rid12">12</a>] if their bronchiectasis is optimally managed [<a href="#rid3">3,13</a>].</p><p></p><p class="bulletIndent1">Optimal management includes:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Early diagnosis – To ensure optimal care and minimize disease progression. (See  <a class="medical medical_review" href="/d/html/6360.html" rel="external">"Bronchiectasis in children: Clinical manifestations and evaluation"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Identification and treatment of underlying causes – Such as immunodeficiencies, aspiration, or structural lesions such as tracheoesophageal fistula  (<a class="graphic graphic_table graphicRef87712" href="/d/graphic/87712.html" rel="external">table 1</a>). (See <a class="local">'Identification and treatment of underlying causes'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Management of acute exacerbations – Includes antibiotics and airway clearance therapies  (<a class="graphic graphic_table graphicRef132697" href="/d/graphic/132697.html" rel="external">table 2</a>). (See <a class="local">'Management of acute pulmonary exacerbations'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Maintenance therapy:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For all patients, this includes airway clearance techniques (chest physiotherapy) and regular monitoring to track disease progression and identify any complications as well as the first appearance of new pathogens. (See <a class="local">'For all patients'</a> below.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For selected patients, this may include antibiotics to eradicate <em>Pseudomonas</em> <em>aeruginosa</em>, chronic antibiotics, inhaled mucolytics, bronchodilators, and/or glucocorticoids. (See <a class="local">'For selected patients'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Supportive care – Measures to improve general lung health, including avoidance of tobacco smoke and other lung irritants, immunizations, optimizing nutrition, and self-management education and support for the child and family. (See <a class="local">'Supportive care'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Management of advanced lung disease – May include management of hemoptysis, supplemental oxygen, surgery, or lung transplantation. (See <a class="local">'Management of advanced lung disease'</a> below.)</p><p></p><p class="bulletIndent1">These steps are detailed in the remainder of this topic review.</p><p></p><p class="headingAnchor" id="H775209514"><span class="h1">IDENTIFICATION AND TREATMENT OF UNDERLYING CAUSES</span><span class="headingEndMark"> — </span>All patients should be thoroughly evaluated to determine if there is a specific cause or contributor to the bronchiectasis, such as a focal bronchial obstruction or an immunodeficiency. Treatment for the underlying disorder may help prevent further progression or, in some cases, even reverse the bronchiectasis  (<a class="graphic graphic_table graphicRef87712" href="/d/graphic/87712.html" rel="external">table 1</a>) [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/d/html/6360.html" rel="external">"Bronchiectasis in children: Clinical manifestations and evaluation"</a> and  <a class="medical medical_review" href="/d/html/6358.html" rel="external">"Bronchiectasis in children: Pathophysiology and causes"</a>.)</p><p>Additional treatable traits include treating any new acquired pathogens (see <a class="local">'Pathogenesis'</a> below) and complications of bronchiectasis. (See <a class="local">'Routine monitoring'</a> below.)</p><p class="headingAnchor" id="H2736114887"><span class="h1">MANAGEMENT OF ACUTE PULMONARY EXACERBATIONS</span><span class="headingEndMark"> — </span>Prompt identification and treatment of acute pulmonary exacerbations is a critical component of management. Exacerbations may be managed as an outpatient or in hospital, and the choice largely depends on the severity.</p><p>Pulmonary exacerbations are common (averaging three episodes/year) and are important drivers of disease progression [<a href="#rid14">14</a>]. They have been shown to impair quality of life (QoL) and are stressful for parents. Severe exacerbations predict subsequent decline in forced expiratory volume in one second (FEV<sub>1</sub>) [<a href="#rid15">15</a>]. Also, exacerbations lead to high resource use [<a href="#rid16">16</a>] and substantial costs when hospitalized (approximately USD $24,500 per hospitalization) [<a href="#rid17">17,18</a>].</p><p class="headingAnchor" id="H2009173918"><span class="h2">Definition</span><span class="headingEndMark"> — </span>We use the following characteristics to define an acute pulmonary exacerbation, as outlined by the European Respiratory Society [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Increased respiratory symptoms (predominantly increased cough with or without increased sputum quantity and/or purulence) for ≥3 days. Other respiratory symptoms may include breathlessness, wheeze, chest pain, or hemoptysis. The presence of dyspnea (increased work of breathing) or hypoxemia suggest a more severe exacerbation (irrespective of duration).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other findings that support the diagnosis but may not be present are:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Changes in chest auscultation findings and chest radiographs</p><p class="bulletIndent2"><span class="glyph">•</span>Systemic symptoms such as fever, fatigue, malaise, or change in child's behavior or appetite</p><p class="bulletIndent2"><span class="glyph">•</span>Laboratory indices of inflammation such as elevated C-reactive protein, neutrophilia, and interleukin-6 (these are not routinely used for clinical decision-making)</p><p class="bulletIndent2"><span class="glyph">•</span>New infiltrates on chest radiograph</p><p></p><p>Other definitions of an acute pulmonary exacerbation have been used but are similar in that they focus primarily on changes in clinical symptoms [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H1482890390"><span class="h2">Pathogenesis</span><span class="headingEndMark"> — </span>Acute exacerbations are associated with increased infection/inflammation and excessive airway secretions. Treatment approaches target these mechanisms. Either viral or bacterial pathogens may be involved:</p><p class="bulletIndent1"><span class="glyph">●</span>Viruses – A virus can be identified at the beginning of 48 to 53 percent of exacerbations [<a href="#rid20">20,21</a>]. The common viruses identified are rhinovirus, coronaviruses, influenza, parainfluenza, adenoviruses, and respiratory syncytial virus, respectively [<a href="#rid20">20,21</a>]. When compared with nonviral exacerbations, viral-related exacerbations tend to be more severe and are more likely to require hospitalization [<a href="#rid22">22</a>]. Although rhinoviruses are common, it is uncertain whether they cause acute exacerbations because it can also be detected in up to 40 percent of asymptomatic children without bronchiectasis [<a href="#rid23">23,24</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bacteria – An important role for bacteria in acute exacerbations is suggested by studies in adults, in whom acute exacerbations are associated with increased bacteria density and inflammation, and treatment reverses these changes, with concurrent improvement in exercise capacity and health-related QoL [<a href="#rid25">25,26</a>]. There are no such studies in children, likely because of the difficulty of obtaining lower airway specimens in young children.</p><p></p><p class="bulletIndent1">The most commonly isolated bacteria in children with bronchiectasis during stable state are non-encapsulated <em>Haemophilus</em> <em>influenzae</em>, <em>Streptococcus</em> <em>pneumonia</em>, <em>Moraxella</em> <em>catarrhalis</em>, and <em>Staphylococcus</em> <em>aureus</em> [<a href="#rid8">8</a>]. <em>P</em>. <em>aeruginosa</em> is rare in high-income pediatric cohort<em>s</em> and in young children but is more often detected in low-income countries, older children, and those with underlying diseases with advanced lung damage [<a href="#rid8">8,27</a>]. Biofilms witho<em>ut</em> <em>P</em>. <em>aeruginosa</em> have been described in the lower airways of children with bronchiectasis [<a href="#rid28">28</a>].</p><p></p><p class="headingAnchor" id="H3427129485"><span class="h2">Antibiotics</span><span class="headingEndMark"> — </span>All published pediatric guidelines recommend using antibiotics to treat bronchiectasis exacerbations  (<a class="graphic graphic_table graphicRef132697" href="/d/graphic/132697.html" rel="external">table 2</a>) [<a href="#rid1">1,29</a>]. The method of administration (oral and/or inhaled or intravenous antibiotics) depends on the severity of the exacerbation. The antibiotic should be selected based on the individual's lower airway microbiology and sensitivities from the most recent sputum cultures (see <a class="local">'Routine monitoring'</a> below). If no recent cultures are available at the time of a pulmonary exacerbation, we initiate empiric antibiotics while waiting for the results of a new sputum culture (in children who are able to expectorate sputum). Bronchoalveolar lavage is occasionally undertaken to obtain lower respiratory tract samples for culture, but its use is limited to patients who fail to respond to usual therapy or if atypical or antibiotic-resistant pathogens are suspected [<a href="#rid3">3</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral antibiotics</strong> – For most children without <em>P</em>. <em>aeruginosa</em> infection, <a class="drug drug_pediatric" data-topicid="12639" href="/d/drug information/12639.html" rel="external">amoxicillin-clavulanate</a> is an appropriate first-line treatment because it covers the common organisms found in children with bronchiectasis [<a href="#rid1">1,21,29</a>]. The typical course of treatment is 14 days. Other oral antibiotics may be selected if the patient is allergic to penicillin or based upon the patient's lower airway microbiology or historical response to antibiotics.</p><p></p><p class="bulletIndent1">The efficacy of <a class="drug drug_pediatric" data-topicid="12639" href="/d/drug information/12639.html" rel="external">amoxicillin-clavulanate</a> was shown in a randomized trial in which it was superior to placebo (BEST-1) [<a href="#rid20">20</a>]. In another trial (BEST-2), <a class="drug drug_pediatric" data-topicid="12937" href="/d/drug information/12937.html" rel="external">azithromycin</a> was effective for nonsevere exacerbations as well but also induced macrolide-resistant organisms and the treatment response was slower than for amoxicillin-clavulanate [<a href="#rid21">21</a>]. Hence, amoxicillin-clavulanate is the first-choice empirical antibiotic but azithromycin might be useful for some patients, such as those with penicillin allergy or those who require less frequent dosing to improve adherence.</p><p></p><p class="bulletIndent1">For children with chron<em>ic</em> <em>P</em>. <em>aeruginosa</em> infection, <a class="drug drug_pediatric" data-topicid="13157" href="/d/drug information/13157.html" rel="external">ciprofloxacin</a> is usually an appropriate first-line choice [<a href="#rid1">1</a>]. Other choices include inhaled aminoglycosides or <a class="drug drug_pediatric" data-topicid="13161" href="/d/drug information/13161.html" rel="external">colistin</a> as the initial treatment, based on culture sensitivities and the child's specific characteristics (eg, some young children are unable to tolerate inhaled antibiotics).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intravenous antibiotics</strong> – Intravenous antibiotics are reserved for severe exacerbations or when symptoms/signs persist after a long course (usually approximately four weeks) of oral antibiotics. For antibiotic selection, it is reasonable to use principles of treatment similar to those used for acute exacerbations in children with cystic fibrosis (CF), which are outlined in a separate topic review. (See  <a class="medical medical_review" href="/d/html/140721.html" rel="external">"Cystic fibrosis: Antibiotic therapy for pulmonary exacerbations"</a>.)</p><p></p><p class="bulletIndent1">In children with bronchiectasis, antipseudomonal antibiotics are only used when there is evidence of presence <em>of</em> <em>P</em>. <em>aeruginosa</em> infection on a lower airway specimen or after the failure of an empiric intravenous antibiotic regimen, which covers the common organisms found in children with bronchiectasis. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="headingAnchor" id="H295344257"><span class="h2">Airway clearance therapy</span><span class="headingEndMark"> — </span>In addition to antibiotics, management of acute exacerbations includes:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Airway clearance techniques</strong> – Airway clearance techniques, also known as chest physiotherapy, should be intensified during acute exacerbations [<a href="#rid1">1</a>]. The goal is to help clear the excessive mucus that is seen in an acute exacerbation. Airway clearance techniques are also an important component of maintenance therapy for bronchiectasis [<a href="#rid30">30,31</a>]. (See <a class="local">'Airway clearance therapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inhaled airway clearance agents</strong> – For children with high sputum load, we suggest treatment with inhaled hypertonic <a class="drug drug_pediatric" data-topicid="12796" href="/d/drug information/12796.html" rel="external">saline</a> (6 to 7%) during an acute exacerbation as an adjunct to antibiotic treatment and airway clearance techniques. Other candidates for this treatment may be identified by an expert pediatric respiratory therapist. The therapy is administered via nebulizer, twice daily, just before performing airway clearance therapy. For some patients, we also use inhaled hypertonic saline as part of maintenance therapy, as discussed below. (See <a class="local">'Inhaled airway hydrating agents and mucolytics'</a> below.)</p><p></p><p class="headingAnchor" id="H68093203"><span class="h1">MAINTENANCE THERAPY</span><span class="headingEndMark"> — </span>The aim of maintenance therapy in children and adolescents with bronchiectasis is to decrease the lower airway inflammation/infection and help prevent pulmonary exacerbations, thereby improving quality of life (QoL), symptom control, and long-term outcomes (eg, preservation and/or improvement of lung function).</p><p class="headingAnchor" id="H2980632769"><span class="h2">For all patients</span></p><p class="headingAnchor" id="H1178461145"><span class="h3">Airway clearance therapy</span><span class="headingEndMark"> — </span>Airway clearance techniques (often called chest physiotherapy) are standard treatment in all bronchiectasis guidelines. Available studies suggest that airway clearance techniques are beneficial with improved QoL and exercise capacity and reduced cough and sputum volumes [<a href="#rid1">1</a>]. Available techniques include chest percussion, positive airway pressure, forced expirations, and exercise. Given the lack of clear superiority of any one technique, specific choices should be individualized and guided by a specialist in pediatric respiratory therapy. The technique(s) should be selected and taught by pediatric therapists to match the child's age and cognitive stage and to maximize potential benefit and minimize the burden of care [<a href="#rid1">1</a>]. Postural drainage, a standard therapy for children with bronchiectasis in the past, is now rarely used as it may increase gastroesophageal reflux disease and possible aspiration. In practice, airway clearance techniques are used more often by patients who have more severe disease compared with those with milder symptoms/disease, as well as in response to symptoms rather than as a preventative management strategy [<a href="#rid32">32</a>].</p><p>Irrespective of the basal frequency, children and adolescents should perform airway clearance therapy more frequently during acute exacerbations of bronchiectasis [<a href="#rid13">13</a>]. (See <a class="local">'Management of acute pulmonary exacerbations'</a> above.)</p><p>In addition, children with bronchiectasis should be encouraged to engage in physical activity. Most children with bronchiectasis have suboptimal levels of physical activity [<a href="#rid33">33</a>]. Barriers to exercise include difficulty keeping up with peers and recreational screen time [<a href="#rid34">34</a>]. While there are no data on the benefits of exercise training, exercise improves airway clearance and exercise training significantly improves cardiovascular fitness and QoL in children with asthma or cystic fibrosis (CF) [<a href="#rid33">33</a>].</p><p class="headingAnchor" id="H1965625990"><span class="h3">Routine monitoring</span><span class="headingEndMark"> — </span>Children with bronchiectasis should be monitored by a pediatric pulmonology specialist. They should generally be seen every three to six months in an outpatient clinic, including the following serial measures [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sputum cultures</strong> – Serial sputum cultures help to guide antibiotic selection should an acute exacerbation occur. In addition, they are used to monitor for the initial acquisition of <em>P</em>. <em>aeruginosa</em> and other pathogens that can cause progressive deterioration (eg, <em>Burkholderia</em> <em>cepacia</em> complex). When present, these require prompt treatment. (See <a class="local">'Early eradication of Pseudomonas aeruginosa'</a> below.)</p><p></p><p class="bulletIndent1">For patients who can expectorate, we obtain a sputum culture approximately every six months. However, this may not be possible, because most children with mild bronchiectasis do not produce sputum in their baseline state and young children may not be able to produce sputum even during an exacerbation. In some cases, sputum induction may be feasible.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Spirometry</strong> – Outside of disease exacerbations, measures of pulmonary function (forced expiratory volume in one second [FEV<sub>1</sub>] and forced vital capacity [FVC]) are often normal for children with mild bronchiectasis and may be abnormal for those with moderate or severe bronchiectasis. An acute decline in FEV<sub>1</sub> (&gt;10 percent) can provide supportive evidence for acute exacerbations, but FEV<sub>1</sub> values may not decline during exacerbations [<a href="#rid20">20,21</a>]. (See  <a class="medical medical_review" href="/d/html/6360.html" rel="external">"Bronchiectasis in children: Clinical manifestations and evaluation", section on 'Spirometry'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulse oximetry</strong> – Most children with bronchiectasis have normal oxygen saturation at rest. Low values are sometimes seen during a severe acute exacerbation or in advanced lung disease and may be helpful in decisions regarding hospitalization and oxygen supplementation. (See <a class="local">'Management of advanced lung disease'</a> below.)</p><p></p><p class="headingAnchor" id="H726035281"><span class="h2">For selected patients</span></p><p class="headingAnchor" id="H2975701482"><span class="h3">Early eradication of <i>Pseudomonas aeruginosa</i></span><span class="headingEndMark"> — </span>New acquisition of <em>P</em>. <em>aeruginosa</em> is associated with exacerbations and/or deteriorating clinical status and lung function [<a href="#rid35">35</a>]. If the sputum culture detects <em>P</em>. <em>aeruginosa</em>, we suggest prompt treatment with antipseudomonal antibiotics in an attempt to eradicate this organism [<a href="#rid1">1</a>], as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Symptomatic patients – For patients with symptoms that are increased compared with their baseline, treat with intravenous antipseudomonal antibiotics (eg, <a class="drug drug_pediatric" data-topicid="12708" href="/d/drug information/12708.html" rel="external">piperacillin-tazobactam</a> or <a class="drug drug_pediatric" data-topicid="13134" href="/d/drug information/13134.html" rel="external">ceftazidime</a> with <a class="drug drug_pediatric" data-topicid="12845" href="/d/drug information/12845.html" rel="external">tobramycin</a>) for two weeks, followed by inhaled antibiotics (tobramycin or <a class="drug drug_pediatric" data-topicid="13161" href="/d/drug information/13161.html" rel="external">colistin</a>) for 4 to 12 weeks.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Asymptomatic patients – For patients who are asymptomatic when the <em>P</em>. <em>aeruginosa</em> is first detected (ie, symptoms unchanged from their baseline), use oral <a class="drug drug_pediatric" data-topicid="13157" href="/d/drug information/13157.html" rel="external">ciprofloxacin</a> and/or inhaled antibiotics (<a class="drug drug_pediatric" data-topicid="12845" href="/d/drug information/12845.html" rel="external">tobramycin</a> or <a class="drug drug_pediatric" data-topicid="13161" href="/d/drug information/13161.html" rel="external">colistin</a>) for two weeks, followed by continued inhaled antibiotics for 4 to 12 weeks.</p><p></p><p>These strategies are based on expert consensus, as outlined in guidance from the European Respiratory Society [<a href="#rid1">1</a>]. The evidence is extrapolated from studies in adults with bronchiectasis that describe improved QoL and reduced exacerbation rates and hospitalizations (compared with pre-eradication) [<a href="#rid36">36-38</a>]. Other evidence is from early eradication regimens in children with CF. No direct evidence is available from children with bronchiectasis unrelated to CF to support the efficacy of early eradication or to guide selection of specific eradication regimens. (See  <a class="medical medical_review" href="/d/html/129310.html" rel="external">"Bronchiectasis in adults: Maintaining lung health", section on 'Eradication of new isolates of Pseudomonas'</a> and  <a class="medical medical_review" href="/d/html/6371.html" rel="external">"Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection", section on 'Prevention and eradication'</a>.)</p><p class="headingAnchor" id="H2172364767"><span class="h3">Chronic antibiotics</span><span class="headingEndMark"> — </span>We suggest chronic antibiotic therapy only for selected children with bronchiectasis  (<a class="graphic graphic_table graphicRef132697" href="/d/graphic/132697.html" rel="external">table 2</a>) [<a href="#rid39">39</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral antibiotics</strong> – We suggest chronic oral antibiotics for children with frequent exacerbations (&gt;3 per year), especially if the exacerbations are severe (ie, requiring hospitalization) [<a href="#rid1">1</a>]. When chronic antibiotic therapy is indicated, we generally suggest a macrolide (eg, <a class="drug drug_pediatric" data-topicid="12937" href="/d/drug information/12937.html" rel="external">azithromycin</a>) because this is the agent that has been studied in randomized trials in this population.</p><p></p><p class="bulletIndent1"><a class="drug drug_pediatric" data-topicid="12937" href="/d/drug information/12937.html" rel="external">Azithromycin</a> can be dosed daily, three times a week, or weekly, with a total dose of approximately 30 mg/kg/week (up to 1500 mg/week). The optimal dose and frequency has not been established for this population; in our practice, we select the frequency of dosing based on patient characteristics. We generally use three-times-a-week dosing but may use weekly dosing in settings where directly observed therapy is required or daily dosing if the child has difficulty tolerating larger doses. Other reasonable antibiotic choices include <a class="drug drug_pediatric" data-topicid="13255" href="/d/drug information/13255.html" rel="external">doxycycline</a> (only for children aged &gt;8 years) or <a class="drug drug_pediatric" data-topicid="12816" href="/d/drug information/12816.html" rel="external">trimethoprim-sulfamethoxazole</a> in children who do not tolerate macrolides, even though there are no data on the efficacy of these antibiotics for children with bronchiectasis.</p><p></p><p class="bulletIndent1">This practice is supported by limited clinical trial data [<a href="#rid1">1,40,41</a>]. The largest trial involved 89 children with non-CF-related bronchiectasis who were randomized to chronic treatment with <a class="drug drug_pediatric" data-topicid="12937" href="/d/drug information/12937.html" rel="external">azithromycin</a> or placebo [<a href="#rid40">40</a>]. At 24 months, azithromycin halved the frequency of exacerbations compared with placebo (rate ratio 0.50, 95% CI 0.35-0.71) [<a href="#rid40">40</a>]. However, children in the azithromycin group developed higher nasal carriage of azithromycin-resistant bacteria (46 versus 11 percent). Despite this, they were significantly less likely (50 percent reduction) to require antibiotics for nonrespiratory acute infections compared with those receiving placebo. A secondary analysis of data from this study showed that the optimal duration of prophylactic azithromycin therapy is between 17 and 62 weeks [<a href="#rid42">42</a>]. Indirect evidence from other populations includes a short-term study in pediatric and adult patients with primary ciliary dyskinesia (a cause for bronchiectasis) [<a href="#rid43">43</a>] and populations with CF. (See  <a class="medical medical_review" href="/d/html/6372.html" rel="external">"Cystic fibrosis: Overview of the treatment of lung disease", section on 'Azithromycin'</a> and  <a class="medical medical_review" href="/d/html/4338.html" rel="external">"Primary ciliary dyskinesia (immotile-cilia syndrome)"</a>.)</p><p></p><p class="bulletIndent1">If macrolides are commenced, additional recommended steps are [<a href="#rid1">1</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Counseling – Utilize counseling strategies to encourage adherence to the regimen. Adherence to ≥70 percent of the regimen increases efficacy and reduces antibiotic resistance [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Sputum culture – Prior to initiating therapy, obtain a sputum specimen (when possible) to exclude the presence of nontuberculous mycobacteria (NTM). These organisms are rarely detected in children/adolescents with bronchiectasis. If NTM are present, monotherapy with a macrolide antibiotic is not recommended, because it can induce drug resistance in the NTM strain. The decision to treat NTM is not straightforward and should be made in consultation with a specialist/expert in the field.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Periodic reassessment – Treat for at least six months, with periodic clinical reassessment to determine whether there is clinical benefit. Clinical reassessment is particularly important if the treatment is continued for 24 months or longer.</p><p></p><p class="bulletIndent2">The recommendation for clinical reassessment reflects a concern that chronic treatment with macrolides may increase antibiotic resistance. Indeed, several studies show that treatment with macrolides promotes the carriage of resistant bacteria [<a href="#rid1">1,40,45</a>]. However, in one of these trials, children in the <a class="drug drug_pediatric" data-topicid="12937" href="/d/drug information/12937.html" rel="external">azithromycin</a> group required 50 percent fewer antibiotics for respiratory exacerbations and also had 50 percent fewer antibiotics for other infections despite the induced resistance [<a href="#rid40">40</a>]. Thus, there were no clear adverse consequences of the treatment-induced changes in antibiotic resistance, at least during the 24-month duration of this trial.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inhaled antibiotics </strong>– For children who are chronically infected with <em>P.</em> <em>aeruginosa </em><strong>and </strong>have frequent exacerbations, oral macrolides are the first-line approach to maintenance treatment, but inhaled <a class="drug drug_pediatric" data-topicid="12845" href="/d/drug information/12845.html" rel="external">tobramycin</a> or <a class="drug drug_pediatric" data-topicid="13161" href="/d/drug information/13161.html" rel="external">colistin</a> may be used as an alternative (eg, for those who cannot tolerate macrolides) or used in conjunction with the oral macrolides. Other options include inhaled <a class="drug drug_pediatric" data-topicid="13157" href="/d/drug information/13157.html" rel="external">ciprofloxacin</a> or <a class="drug drug_pediatric" data-topicid="13332" href="/d/drug information/13332.html" rel="external">gentamicin</a>. By contrast, children with clinically stable bronchiectasis should not be treated with chronic inhaled antibiotics [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1">This strategy is based on indirect evidence from patients with either CF-related bronchiectasis or adult patients with bronchiectasis and chronic <em>P</em>. <em>aeruginosa</em> infection [<a href="#rid46">46</a>]. As an example, a randomized trial in adults found that chronic treatment with inhaled <a class="drug drug_pediatric" data-topicid="13161" href="/d/drug information/13161.html" rel="external">colistin</a> decreased the annual rate of exacerbations, prolonged time to first exacerbation, and decreased severe exacerbations [<a href="#rid47">47</a>]. (See  <a class="medical medical_review" href="/d/html/6371.html" rel="external">"Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection", section on 'Inhaled antibiotics'</a>.)</p><p></p><p>The guidance on chronic antibiotic use outlined above is based primarily on expert opinion and clinical experience; limited data are available to guide selection of patients for treatment, antibiotic selection, and route of administration (oral versus inhaled) [<a href="#rid13">13,39</a>].</p><p class="headingAnchor" id="H3243586269"><span class="h3">Inhaled airway hydrating agents and mucolytics</span><span class="headingEndMark"> — </span>We suggest using either inhaled hypertonic <a class="drug drug_pediatric" data-topicid="12796" href="/d/drug information/12796.html" rel="external">saline</a> (6 or 7%) or <a class="drug drug_pediatric" data-topicid="12570" href="/d/drug information/12570.html" rel="external">mannitol</a> as part of the chronic regimen for children with moderate or severe, high, daily symptoms; frequent exacerbations; difficulty in expectoration; and/or poor QoL, consistent with European and Australia/New Zealand guidelines [<a href="#rid1">1,39</a>]. Most of these children should also be treated with chronic oral macrolide antibiotics (see <a class="local">'Chronic antibiotics'</a> above). Because these inhaled therapies can cause bronchospasm, the first dose should be administered under medical supervision and subsequent doses should be preceded by a bronchodilator to prevent bronchospasm.</p><p>The therapy is administered twice daily in the following sequence:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="13290" href="/d/drug information/13290.html" rel="external">Albuterol</a> by metered-dose inhaler (to help prevent bronchospasm during therapy)</p><p class="bulletIndent1"><span class="glyph">●</span>Inhaled hypertonic <a class="drug drug_pediatric" data-topicid="12796" href="/d/drug information/12796.html" rel="external">saline</a> (6 or 7%) by nebulizer <strong>or</strong> <a class="drug drug_pediatric" data-topicid="12570" href="/d/drug information/12570.html" rel="external">mannitol</a> by dry powder inhaler</p><p class="bulletIndent1"><span class="glyph">●</span>Routine airway clearance therapy (chest physiotherapy)</p><p></p><p>The use of hypertonic saline is primarily based on indirect evidence from patients with CF or from adults with bronchiectasis [<a href="#rid48">48,49</a>]. The only direct evidence in children with bronchiectasis unrelated to CF is from a small randomized crossover trial, which found that incorporating hypertonic saline into the airway clearance regimen improved spirometric parameters (FEV<sub>1</sub> and FVC) [<a href="#rid50">50</a>]. However, a reduction in frequency of exacerbations was only found in the first phase of the study and not in the second phase (after crossover). Of note, this trial used a lower concentration of hypertonic saline (3%) than is typically used in clinical settings (6 or 7%).</p><p>Inhaled dry powder <a class="drug drug_pediatric" data-topicid="12570" href="/d/drug information/12570.html" rel="external">mannitol</a> is generally well tolerated and may have some modest benefits for airway clearance in adult bronchiectasis [<a href="#rid51">51,52</a>], but pediatric data are unavailable. Compared with hypertonic saline, mannitol is somewhat easier to administer but can only be used in older children (who are able to cooperate) and is more expensive.</p><p><a class="drug drug_pediatric" data-topicid="13239" href="/d/drug information/13239.html" rel="external">Acetylcysteine</a> (oral or inhaled) has been studied in adults with bronchiectasis, but there is insufficient evidence to support its use. Dornase alpha (<a class="drug drug_pediatric" data-topicid="13249" href="/d/drug information/13249.html" rel="external">DNase</a>) is an established therapy for patients with CF but is not effective and may be harmful in other patients with bronchiectasis, based on studies in adults, and thus is contraindicated. (See  <a class="medical medical_review" href="/d/html/129310.html" rel="external">"Bronchiectasis in adults: Maintaining lung health", section on 'Mucolytic agents and airway hydration'</a>.)</p><p class="headingAnchor" id="H1783845191"><span class="h3">Bronchodilators and glucocorticoids</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bronchodilators</strong> – Inhaled bronchodilators (beta agonists) are indicated in the following situations [<a href="#rid1">1</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>As pretreatment before use of inhaled hypertonic <a class="drug drug_pediatric" data-topicid="12796" href="/d/drug information/12796.html" rel="external">saline</a> or <a class="drug drug_pediatric" data-topicid="12570" href="/d/drug information/12570.html" rel="external">mannitol</a> (when those treatments are otherwise indicated)</p><p class="bulletIndent2"><span class="glyph">•</span>For children with coexisting asthma or definite bronchial hyperreactivity (chronic or intermittent use)</p><p></p><p class="bulletIndent1">For all other patients, there is no evidence to support the routine use of bronchodilators, as there is no evidence of general beneficial effects including on mucociliary clearance [<a href="#rid1">1,53,54</a>]. Rarely, paradoxical response to bronchodilators has been reported in some adults with chronic obstructive pulmonary disease (COPD) and bronchiectasis [<a href="#rid55">55,56</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inhaled glucocorticoids</strong> – Inhaled glucocorticoids, alone or in combination with bronchodilators, are indicated only for patients with concomitant asthma, as documented with an objective evaluation of airway hyperreactivity and/or eosinophilic airway inflammation [<a href="#rid1">1</a>]. Otherwise, there is no evidence to support their routine use for pediatric or adult patients with bronchiectasis [<a href="#rid1">1,57,58</a>]. (See  <a class="medical medical_review" href="/d/html/129310.html" rel="external">"Bronchiectasis in adults: Maintaining lung health", section on 'Anti-inflammatory medications'</a>.)</p><p></p><p class="bulletIndent1">Lack of general benefit from inhaled glucocorticoids was suggested by a small study in children with bronchiectasis who were chronically treated with inhaled glucocorticoids at baseline [<a href="#rid59">59</a>]. Withdrawal of the glucocorticoids caused no change in the frequency of exacerbations, antibiotic use, or inflammatory markers. Some patients had an increase in bronchial hyperreactivity detected with provocative testing.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral glucocorticoids</strong> – Oral glucocorticoids are indicated only for selected patients with an exacerbation of concomitant asthma (brief course) or other indications for treatment of coexistent disease, such as allergic bronchopulmonary aspergillosis. (See  <a class="medical medical_review" href="/d/html/5740.html" rel="external">"Acute asthma exacerbations in children younger than 12 years: Emergency department management", section on 'Management of inflammation'</a> and  <a class="medical medical_review" href="/d/html/104431.html" rel="external">"Treatment of allergic bronchopulmonary aspergillosis"</a>.)</p><p></p><p class="bulletIndent1">Except for the above indications, systemic glucocorticoids should be avoided for children with bronchiectasis because they depress host immunity, may perpetuate infection, and have adverse effects on growth [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>.)</p><p></p><p class="headingAnchor" id="H2995062702"><span class="h1">SUPPORTIVE CARE</span></p><p class="headingAnchor" id="H1336192622"><span class="h2">General measures to improve health</span><span class="headingEndMark"> — </span>The following measures prevent or reduce the severity of respiratory infections and thereby reduce the risk for developing or the progression of bronchiectasis:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Avoidance of smoke and other irritants</strong> – All individuals with bronchiectasis should avoid respiratory irritants, including smoking or exposure to secondhand smoke or vapor from electronic cigarettes (e-cigarettes). Children should be given anticipatory guidance to prevent smoking and vaping initiation, and household members should be counseled and supported in smoking and vaping cessation. Other irritants, such as wood smoke from fires and environmental pollutants, should also be avoided. (See  <a class="medical medical_review" href="/d/html/6376.html" rel="external">"Control of secondhand smoke exposure"</a> and  <a class="medical medical_review" href="/d/html/14583.html" rel="external">"Prevention of smoking and vaping initiation in children and adolescents"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vaccines</strong> – Rigorous attention should be given to vaccinations, ensuring timely completion of all routine childhood vaccination series, and particularly the influenza and pneumococcal vaccines. (See  <a class="medical medical_review" href="/d/html/2876.html" rel="external">"Standard immunizations for children and adolescents: Overview"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Influenza vaccination should be given annually. The <a class="drug drug_pediatric" data-topicid="12940" href="/d/drug information/12940.html" rel="external">inactivated influenza vaccine</a> (intramuscular) must be used for any child who might be immunocompromised. The <a class="drug drug_pediatric" data-topicid="12941" href="/d/drug information/12941.html" rel="external">live attenuated influenza vaccine</a> (intranasal) should not be given if there is any possibility that the child is immunocompromised. (See  <a class="medical medical_review" href="/d/html/5960.html" rel="external">"Seasonal influenza in children: Prevention with vaccines"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>All children with bronchiectasis should receive the standard pneumococcal conjugate vaccine series (either <a class="drug drug_pediatric" data-topicid="139114" href="/d/drug information/139114.html" rel="external">15-valent pneumococcal conjugate vaccine</a> [PCV15] or <a class="drug drug_pediatric" data-topicid="141485" href="/d/drug information/141485.html" rel="external">20-valent pneumococcal conjugate vaccine</a> [PCV20]), as is recommended for healthy children. Children with bronchiectasis and other chronic respiratory illnesses are considered at high risk of invasive pneumococcal disease and may require additional pneumococcal vaccination if their primary series did not include at least one dose of PCV20. This is discussed separately. (See  <a class="medical medical_review" href="/d/html/6053.html" rel="external">"Pneumococcal vaccination in children", section on 'Immunization of high-risk children and adolescents'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nutrition</strong> – Monitoring nutritional status and growth and optimizing nutrition are important components of health care for children with bronchiectasis, as for children with other chronic illnesses [<a href="#rid1">1</a>]. Growth parameters should be measured at each office visit and tracked on standard growth charts. Children with suboptimal growth warrant intervention, which may include nutritional counseling and sometimes supplemental feeding. (See  <a class="medical medical_review" href="/d/html/2877.html" rel="external">"Poor weight gain in children older than two years in resource-abundant settings"</a> and  <a class="medical medical_review" href="/d/html/2874.html" rel="external">"Poor weight gain in children younger than two years in resource-abundant settings: Management"</a>.)</p><p></p><p class="bulletIndent1">Children with bronchiectasis are at risk for undernutrition. As an example, one study found that children with bronchiectasis were three times more likely to have had malnutrition in early childhood before the diagnosis of bronchiectasis compared with matched controls [<a href="#rid60">60</a>].</p><p></p><p class="bulletIndent1">In addition, poor nutrition is associated with worse lung function. As examples, a retrospective study in children with bronchiectasis showed that worse nutritional state at the time of initial evaluation was associated with abnormal lung function [<a href="#rid61">61</a>]. Similarly, studies in adults show that underweight patients with bronchiectasis had lower lung function (forced expiratory volume in one second [FEV<sub>1</sub>] percent predicted) compared with those with healthy weight (64.5±22 versus 73.5±21) [<a href="#rid62">62</a>]. Finally, a large population-based study of 2769 adults with bronchiectasis showed that underweight was associated with increased all-cause mortality among individuals with bronchiectasis [<a href="#rid63">63</a>].</p><p></p><p class="bulletIndent1">Some of the medical interventions directed at treating the bronchiectasis may improve nutritional status. In the randomized trial of <a class="drug drug_pediatric" data-topicid="12937" href="/d/drug information/12937.html" rel="external">azithromycin</a> for children with bronchiectasis, weight Z-scores improved in children treated with six months of azithromycin compared with placebo [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vitamin D deficiency</strong> – Vitamin D deficiency is common among children and adults with bronchiectasis [<a href="#rid1">1,64</a>]. 25-hydroxyvitamin D concentrations should be monitored periodically and supplementation given to children who are deficient. (See  <a class="medical medical_review" href="/d/html/14590.html" rel="external">"Vitamin D insufficiency and deficiency in children and adolescents"</a>.)</p><p></p><p class="bulletIndent1">The possibility has been raised that vitamin D deficiency may contribute to the pathogenesis of bronchiectasis. Vitamin D is known to have antiinfective and antiinflammatory properties, as shown in animal models and in vitro studies [<a href="#rid65">65-67</a>]. In addition, a correlation between vitamin D status and disease severity has been shown in multiple studies in children and adults with bronchiectasis [<a href="#rid64">64,68,69</a>]. However, a causal effect of vitamin D deficiency on bronchiectasis has not been established and there is no evidence that supraphysiologic doses of vitamin D are beneficial for patients with bronchiectasis. Indeed, the correlation may reflect the adverse effects of bronchiectasis on nutritional status (reverse causation).</p><p></p><p class="headingAnchor" id="H561903630"><span class="h2">Education and support</span><span class="headingEndMark"> — </span>Self-management education and support is an important part of chronic disease management and is desired by patients [<a href="#rid70">70,71</a>]. In adults with bronchiectasis, adherence to treatment can be low (16 percent), but those patients who do adhere to treatment have fewer exacerbations and lower perceived treatment burden [<a href="#rid72">72</a>].</p><p>Self-management education may include:</p><p class="bulletIndent1"><span class="glyph">●</span>Information about the likely cause of the child's bronchiectasis and expected clinical course</p><p class="bulletIndent1"><span class="glyph">●</span>How to reduce the risk of exacerbations (eg, avoiding smoke and other irritants, measures to avoid respiratory illnesses)</p><p class="bulletIndent1"><span class="glyph">●</span>Personalized plan for maintenance therapy (including airway clearance therapy and immunizations)</p><p class="bulletIndent1"><span class="glyph">●</span>Age-appropriate, regular physical activity</p><p class="bulletIndent1"><span class="glyph">●</span>How to recognize infective exacerbations and initiate antibiotic treatment (dose and duration)</p><p class="bulletIndent1"><span class="glyph">●</span>Personalized action plan for managing exacerbations</p><p class="bulletIndent1"><span class="glyph">●</span>Coordination of care with the primary care clinician on a regular basis</p><p class="bulletIndent1"><span class="glyph">●</span>Contact information for the bronchiectasis care team, including plans for emergency communication</p><p></p><p>A <a class="external" href="/external-redirect?target_url=https%3A%2F%2F9ce17ecd-1a82-473c-821b-7a25cac613b2.filesusr.com%2Fugd%2Facf027_7e9adb333fbf4f03b2ee8a5ab0087aab.pdf&amp;token=jDI96ue%2BupzILN0aLhhoHRBpwyhEWxR91bOLY%2Fb%2Fc37ZQEV5Pu9p4r6qr93Td1jIrzF8byi%2Fvk9lUXOOvcUo3Q0CJoJQrPieHvC49vKdJSpsCYWucte2Q22eyqlBb6RxquQbHSpw%2FEF1LZdjhgRtMg%3D%3D&amp;TOPIC_ID=6355" target="_blank">template for a bronchiectasis action management plan</a> is available from the Children's Bronchiectasis Education, Advocacy and Research Network [<a href="#rid73">73</a>]. Self-management education programs for bronchiectasis have not been standardized or studied [<a href="#rid74">74</a>]. Studies in adults and children are in progress [<a href="#rid75">75</a>].</p><p>Children with bronchiectasis and their families also require psychological support to address disease-related stressors, anxiety, and depression. They also require support regarding care of equipment (eg, airway clearance and nebulizers). In an international survey, the top five burdens of bronchiectasis that affected children's quality of life (QoL) as reported by parents are doing airway clearance therapy, medications, exacerbations, symptom/disease management, and cough [<a href="#rid18">18</a>]. The top features that affected the parents' QoL were dedicated time needed to care for the child, challenges of obtaining medical assistance, and strategies to prevent infection.</p><p class="headingAnchor" id="H3171274447"><span class="h2">Transition to adult care systems</span><span class="headingEndMark"> — </span>Adolescents with bronchiectasis require extra support and guidance during the transition to adult health care systems, similar to adolescents with other chronic diseases. Poor transitional care may lead to deterioration in health [<a href="#rid76">76,77</a>]. Most pediatric hospitals have a policy on transition, but there are no universally accepted, quality metrics specific for transition care. The Australian and New Zealand guideline recommended that "health services should provide transitional care that supports the requirements of adolescents with bronchiectasis. A purposeful, planned and developmentally appropriate transition, which includes engagement of the pediatric and adult multidisciplinary teams, utilization of transition guidelines, and clear documentation of transfer processes are key goals as they transition from child to adult health services" [<a href="#rid39">39</a>].</p><p class="headingAnchor" id="H2393611464"><span class="h2">Internet resources</span><span class="headingEndMark"> — </span>Online resources related to bronchiectasis for health care providers and families include:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.improvebe.org%2Fnews-resources&amp;token=bJ98wEjwYbR6KcGnbD%2BLoalTyJ1GmlBsFbfiAWGWnqRo9RM%2FC0joYC9drD5gVK%2FKrwC1JCwUsNIWoeWxLU0oqw%3D%3D&amp;TOPIC_ID=6355" target="_blank">Children's Bronchiectasis Education, Advocacy and Research Network</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fcrelungs.org.au%2Fresources&amp;token=x5%2BVcoCrpjS3jaeNhv9xhJD9HvHmXjTDzRCnKbm7qPTU5gvEe3Xe5AZ6yARo%2Bimb&amp;TOPIC_ID=6355" target="_blank">Centre for Research Excellence in Lung Health</a> – Especially for First Nations children in Australia</p><p></p><p class="headingAnchor" id="H3419043273"><span class="h1">MANAGEMENT OF ADVANCED LUNG DISEASE</span></p><p class="headingAnchor" id="H1115794997"><span class="h2">Complications</span><span class="headingEndMark"> — </span>Complications and comorbidities of bronchiectasis are shown in the table  (<a class="graphic graphic_table graphicRef132699" href="/d/graphic/132699.html" rel="external">table 3</a>). Particular attention should be paid to hemoptysis and hypoxemia, which tend to be associated with advanced bronchiectasis.</p><p class="headingAnchor" id="H1701663645"><span class="h3">Hemoptysis</span><span class="headingEndMark"> — </span>Any degree of hemoptysis warrants attention. In a study of 300 children admitted to intensive care with hemoptysis in the United States, bronchiectasis was the cause in 10 percent and was an independent risk factor for in-hospital mortality [<a href="#rid78">78</a>].</p><p>Management of hemoptysis depends upon the cause and severity. Children with hemoptysis should be carefully monitored, and most require hospitalization.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Small-volume hemoptysis</strong> – When the hemoptysis is small volume and mixed with purulent sputum, it is usually related to an acute pulmonary exacerbation and often resolves with appropriate management for the exacerbation. (See <a class="local">'Management of acute pulmonary exacerbations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Large-volume hemoptysis</strong> – Large-volume hemoptysis is rare in children with bronchiectasis but may be life-threatening. When present, it indicates abnormal bronchial artery and/or neovascularization with bronchopulmonary anastomoses in the distal branches of bronchi. The abnormal anastomoses and bronchial artery hyperplasia can increase bronchial blood flow to as much as one-third of the cardiac output [<a href="#rid79">79</a>]. As bronchiectasis progresses in severity, the bronchial artery diameter increases, which escalates the risk and life-threatening consequences of hemoptysis [<a href="#rid80">80</a>].</p><p></p><p>Management of hemoptysis is discussed separately. (See  <a class="medical medical_review" href="/d/html/6370.html" rel="external">"Hemoptysis in children"</a>.)</p><p class="headingAnchor" id="H2032835325"><span class="h3">Hypoxemia</span><span class="headingEndMark"> — </span>For children with severe bronchiectasis and intermittent or chronic hypoxemia, we suggest supplemental oxygen. This is rare, and the management is extrapolated from the management of patients with advanced cystic fibrosis (CF)-related lung disease or chronic obstructive pulmonary disease (COPD).</p><p>In the COPD population, chronic hypoxemia and airway obstruction are known to contribute to vascular remodeling of the pulmonary arteries and arterioles [<a href="#rid81">81</a>], increasing the risk of pulmonary hypertension. Supplemental oxygen delays or ameliorates the complications of chronic hypoxemia, which include adverse effects on physical and cognitive function and quality of life (QoL). (See  <a class="medical medical_review" href="/d/html/1445.html" rel="external">"Long-term supplemental oxygen therapy"</a>.)</p><p class="headingAnchor" id="H1614629773"><span class="h2">Surgery</span><span class="headingEndMark"> — </span>Surgery to remove lobes affected by bronchiectasis is uncommon in children in high-income countries. It is more common in low-resource settings, where bronchiectasis is more likely to be severe and poorly controlled [<a href="#rid82">82-85</a>].</p><p>Lobectomy should only be considered after maximal medical therapies have failed and when the child's QoL remains significantly impaired [<a href="#rid1">1</a>]. This is more common in low- and middle-income countries, where approximately 20 percent of pediatric patients with bronchiectasis unrelated to CF are candidates for lobectomy, due to socioeconomic constraints and barriers to adhering to optimal therapy [<a href="#rid86">86</a>]. Candidates for lobectomy are patients with severe localized disease and/or recurrent hemoptysis that can be addressed by resection of a bronchiectatic lobe. Other important considerations are the underlying etiology of the bronchiectasis (which can predict disease progression) and availability of appropriate surgical expertise and perioperative care.</p><p>Evidence is limited regarding outcomes after surgical management of bronchiectasis. While there are many reports on its benefit, most are from one country with no matching comparisons. In one retrospective study in children with bronchiectasis unrelated to CF, outcomes for 29 children who underwent lobectomy were compared with an age-matched group who were managed medically [<a href="#rid87">87</a>]. The groups had similar outcomes including frequency of acute pulmonary exacerbations, pulmonary function tests, and body mass index Z-scores, suggesting that surgical management had no significant effect. However, this study may have had suboptimal matching because the surgical group had indicators of more severe disease at baseline (clubbing and growth delay). Better surgical outcomes were described in a meta-analysis that included a subgroup of five pediatric studies, in which approximately 60 percent of children had resolution of symptoms and 37 percent had improvement, with acceptable morbidity (13.5 percent) and mortality (2.5 percent) [<a href="#rid88">88</a>].</p><p>Lung transplant is an option for children with advanced lung disease. Although lung transplantation is often used for advanced lung disease in patients with CF, it is rarely needed in pediatric bronchiectasis [<a href="#rid89">89,90</a>].</p><p class="headingAnchor" id="H47198611"><span class="h1">INVESTIGATIONAL THERAPIES</span><span class="headingEndMark"> — </span>Investigational therapies, undertaken only in adults with bronchiectasis, are discussed in a separate topic review (see  <a class="medical medical_review" href="/d/html/1435.html" rel="external">"Bronchiectasis in adults: Treatment of acute and recurrent exacerbations", section on 'Experimental approaches'</a>). Studies are underway to identify the biomarkers of host response to various treatments and long-term outcomes in patients with bronchiectasis [<a href="#rid91">91</a>].</p><p class="headingAnchor" id="H1749772465"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>In early stages, pediatric bronchiectasis can be stabilized and even reversed [<a href="#rid6">6,92</a>]. This contradicts the traditional experience in adults, in which bronchiectasis was traditionally defined as an irreversible dilatation of the airways.</p><p>Across a broader range of severity, optimal management can lead to stabilization or improvement in lung function [<a href="#rid12">12,15,61</a>]. As an example, in a study of 131 indigenous children with long-term follow-up (median nine years after diagnosis), rates of acute lower respiratory infections declined with advancing age and median forced expiratory volume in one second (FEV<sub>1</sub>) was 90 percent predicted (interquartile range 81 to 105) [<a href="#rid93">93</a>]. These encouraging respiratory outcomes in late childhood or early adolescence reflect optimal management of these patients in a multidisciplinary setting. By contrast, other studies describe higher rates of disease progression (eg, 30 percent) and mortality (7 percent) [<a href="#rid94">94</a>].</p><p class="headingAnchor" id="H3810645292"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/116208.html" rel="external">"Society guideline links: Bronchiectasis"</a> and  <a class="medical medical_society_guidelines" href="/d/html/118986.html" rel="external">"Society guideline links: Hemoptysis"</a> and  <a class="medical medical_society_guidelines" href="/d/html/122199.html" rel="external">"Society guideline links: Primary ciliary dyskinesia"</a>.)  </p><p class="headingAnchor" id="H375611384"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/86714.html" rel="external">"Patient education: Bronchiectasis in children (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H12"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Causes of bronchiectasis</strong> – Although cystic fibrosis (CF) is the most common cause of pediatric bronchiectasis in resource-abundant settings, other causes predominate worldwide  (<a class="graphic graphic_table graphicRef87712" href="/d/graphic/87712.html" rel="external">table 1</a>). Pediatric bronchiectasis unrelated to CF remains underrecognized, undertreated, and underserviced. Early diagnosis of bronchiectasis and treatment of underlying causes are critical. (See <a class="local">'Identification and treatment of underlying causes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute pulmonary exacerbations</strong> – Acute exacerbations should be promptly treated with antibiotics, which are selected empirically or, ideally, based on sputum culture results  (<a class="graphic graphic_table graphicRef132697" href="/d/graphic/132697.html" rel="external">table 2</a>). Oral antibiotics (eg, <a class="drug drug_pediatric" data-topicid="12639" href="/d/drug information/12639.html" rel="external">amoxicillin-clavulanate</a> for 14 days) are used for mild exacerbations. Intravenous antibiotics are used for severe exacerbations or for nonresponders to oral antibiotics. Airway clearance therapy should also be intensified during an acute exacerbation. (See <a class="local">'Management of acute pulmonary exacerbations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Maintenance therapy</strong> – Medical therapies are outlined in the table  (<a class="graphic graphic_table graphicRef132697" href="/d/graphic/132697.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>All patients</strong> – Optimal maintenance therapy for children with bronchiectasis includes:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Airway clearance therapy (chest physiotherapy) using an age-appropriate technique. The frequency depends on the child's characteristics. Available techniques include chest percussion, positive airway pressure, forced expirations, and exercise. (See <a class="local">'Airway clearance therapy'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Routine monitoring, consisting of multidisciplinary clinical review, spirometry, sputum culture, and pulse oximetry. (See <a class="local">'Routine monitoring'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Selected patients</strong> – Additional measures for selected patients are:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>When <em>Pseudomonas</em> <em>aeruginosa</em> is first detected in sputum cultures, we suggest early eradication with a course of antipseudomonal antibiotics rather than no treatment (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). This is based on expert opinion and indirect evidence from studies of early eradication in CF and in adults with bronchiectasis. A typical regimen is intravenous antibiotics for two weeks, followed by continued inhaled antibiotics for 4 to 12 weeks. (See <a class="local">'Early eradication of Pseudomonas aeruginosa'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with frequent exacerbations (&gt;3 times per year), we suggest initiating chronic prophylactic antibiotics (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). For most patients, we suggest a macrolide (eg, <a class="drug drug_pediatric" data-topicid="12937" href="/d/drug information/12937.html" rel="external">azithromycin</a>) as the preferred agent for chronic antibiotic therapy rather than other antibiotics (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Limited clinical trial data suggest that chronic prophylactic antibiotic therapy reduces the frequency of exacerbations; however, it also promotes the carriage of resistant bacteria. We prefer azithromycin because it is the agent that has been studied in this population, as well as in patients with CF. Inhaled <a class="drug drug_pediatric" data-topicid="12845" href="/d/drug information/12845.html" rel="external">tobramycin</a> or <a class="drug drug_pediatric" data-topicid="13161" href="/d/drug information/13161.html" rel="external">colistin</a> may be used as an alternative or in addition to chronic oral antibiotics in children who are chronically infected with <em>P</em>. <em>aeruginosa</em> who have frequent exacerbations. (See <a class="local">'Chronic antibiotics'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For children with moderate or severe daily symptoms, frequent exacerbations, and/or difficulty in expectoration, we suggest routine use of either inhaled hypertonic <a class="drug drug_pediatric" data-topicid="12796" href="/d/drug information/12796.html" rel="external">saline</a> (6 or 7%) or inhaled dry powder <a class="drug drug_pediatric" data-topicid="12570" href="/d/drug information/12570.html" rel="external">mannitol</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). The treatment should be given twice daily before airway clearance techniques. Each dose should be preceded by a bronchodilator to reduce the risk of bronchospasm. (See <a class="local">'Inhaled airway hydrating agents and mucolytics'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Children with coexisting asthma or definite bronchial hyperreactivity should be treated with bronchodilators and inhaled glucocorticoids as indicated for the asthma. For children without coexisting asthma, these drugs should not be used (except as pretreatment for inhaled therapy, as noted above), as there is no evidence that they are beneficial. (See <a class="local">'Bronchodilators and glucocorticoids'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supportive care</strong> – Other important aspects of care include avoiding smoke and other respiratory irritants and ensuring optimal nutrition and immunizations. In addition, self-management education and support can improve adherence and outcomes, which may include an <a class="external" href="/external-redirect?target_url=https%3A%2F%2F9ce17ecd-1a82-473c-821b-7a25cac613b2.filesusr.com%2Fugd%2Facf027_7e9adb333fbf4f03b2ee8a5ab0087aab.pdf&amp;token=jDI96ue%2BupzILN0aLhhoHRBpwyhEWxR91bOLY%2Fb%2Fc37ZQEV5Pu9p4r6qr93Td1jIrzF8byi%2Fvk9lUXOOvcUo3Q0CJoJQrPieHvC49vKdJSpsCYWucte2Q22eyqlBb6RxquQbHSpw%2FEF1LZdjhgRtMg%3D%3D&amp;TOPIC_ID=6355" target="_blank">individualized bronchiectasis action management plan</a>. (See <a class="local">'Supportive care'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – With optimal management of pediatric bronchiectasis, lung function often stabilizes or improves with age. A minority of children progress to advanced lung disease. Complications of advanced lung disease include hemoptysis, which can be life-threatening, and (rarely) hypoxemia  (<a class="graphic graphic_table graphicRef132699" href="/d/graphic/132699.html" rel="external">table 3</a>). (See <a class="local">'Management of advanced lung disease'</a> above and <a class="local">'Prognosis'</a> above.)</p><p></p><p class="headingAnchor" id="H2456199019"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Khoulood Fakhoury, MD, and Adaobi Kanu, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Chang AB, Fortescue R, Grimwood K, et al. European Respiratory Society guidelines for the management of children and adolescents with bronchiectasis. Eur Respir J 2021; 58.</a></li><li><a class="nounderline abstract_t">Kapur N, Masel JP, Watson D, et al. Bronchoarterial ratio on high-resolution CT scan of the chest in children without pulmonary pathology: need to redefine bronchial dilatation. Chest 2011; 139:1445.</a></li><li><a class="nounderline abstract_t">Chang AB, Bush A, Grimwood K. Bronchiectasis in children: diagnosis and treatment. Lancet 2018; 392:866.</a></li><li><a class="nounderline abstract_t">Chotirmall SH, Chalmers JD. Bronchiectasis: an emerging global epidemic. BMC Pulm Med 2018; 18:76.</a></li><li><a class="nounderline abstract_t">Prentice BJ, Wales S, Doumit M, et al. Children with bronchiectasis have poorer lung function than those with cystic fibrosis and do not receive the same standard of care. Pediatr Pulmonol 2019; 54:1921.</a></li><li><a class="nounderline abstract_t">Haidopoulou K, Calder A, Jones A, et al. Bronchiectasis secondary to primary immunodeficiency in children: longitudinal changes in structure and function. Pediatr Pulmonol 2009; 44:669.</a></li><li><a class="nounderline abstract_t">Nathan AM, Muthusamy A, Thavagnanam S, et al. Chronic suppurative lung disease in a developing country: impact on child and parent. Pediatr Pulmonol 2014; 49:435.</a></li><li><a class="nounderline abstract_t">Kapur N, Grimwood K, Masters IB, et al. Lower airway microbiology and cellularity in children with newly diagnosed non-CF bronchiectasis. Pediatr Pulmonol 2012; 47:300.</a></li><li><a class="nounderline abstract_t">van der Gast CJ, Cuthbertson L, Rogers GB, et al. Three clinically distinct chronic pediatric airway infections share a common core microbiota. Ann Am Thorac Soc 2014; 11:1039.</a></li><li><a class="nounderline abstract_t">Pizzutto SJ, Yerkovich ST, Upham JW, et al. Children with chronic suppurative lung disease have a reduced capacity to synthesize interferon-gamma in vitro in response to non-typeable Haemophilus influenzae. PLoS One 2014; 9:e104236.</a></li><li><a class="nounderline abstract_t">Chalmers JD, Chang AB, Chotirmall SH, et al. Bronchiectasis. Nat Rev Dis Primers 2018; 4:45.</a></li><li><a class="nounderline abstract_t">Collaro AJ, Chang AB, Marchant JM, et al. Pediatric Patients of Outreach Specialist Queensland Clinics Have Lung Function Improvement Comparable to That of Tertiary Pediatric Patients. Chest 2020; 158:1566.</a></li><li><a class="nounderline abstract_t">Chang AB, Boyd J, Bush A, et al. International consensus statement on quality standards for managing children/adolescents with bronchiectasis from the ERS CRC Child-BEAR-Net. Eur Respir J 2022; 59.</a></li><li><a class="nounderline abstract_t">Amati F, Simonetta E, Gramegna A, et al. The biology of pulmonary exacerbations in bronchiectasis. Eur Respir Rev 2019; 28.</a></li><li><a class="nounderline abstract_t">Kapur N, Masters IB, Chang AB. Longitudinal growth and lung function in pediatric non-cystic fibrosis bronchiectasis: what influences lung function stability? Chest 2010; 138:158.</a></li><li><a class="nounderline abstract_t">Lovie-Toon YG, Grimwood K, Byrnes CA, et al. Health-resource use and quality of life in children with bronchiectasis: a multi-center pilot cohort study. BMC Health Serv Res 2019; 19:561.</a></li><li><a class="nounderline abstract_t">Goyal V, McPhail SM, Hurley F, et al. Cost of hospitalization for bronchiectasis exacerbation in children. Respirology 2020; 25:1250.</a></li><li><a class="nounderline abstract_t">Chang AB, Boyd J, Bell L, et al. Clinical and research priorities for children and young people with bronchiectasis: an international roadmap. ERJ Open Res 2021; 7.</a></li><li><a class="nounderline abstract_t">Kapur N, Masters IB, Morris PS, et al. Defining pulmonary exacerbation in children with non-cystic fibrosis bronchiectasis. Pediatr Pulmonol 2012; 47:68.</a></li><li><a class="nounderline abstract_t">Goyal V, Grimwood K, Ware RS, et al. Efficacy of oral amoxicillin-clavulanate or azithromycin for non-severe respiratory exacerbations in children with bronchiectasis (BEST-1): a multicentre, three-arm, double-blind, randomised placebo-controlled trial. Lancet Respir Med 2019; 7:791.</a></li><li><a class="nounderline abstract_t">Goyal V, Grimwood K, Byrnes CA, et al. Amoxicillin-clavulanate versus azithromycin for respiratory exacerbations in children with bronchiectasis (BEST-2): a multicentre, double-blind, non-inferiority, randomised controlled trial. Lancet 2018; 392:1197.</a></li><li><a class="nounderline abstract_t">Goyal V, Grimwood K, Marchant J, et al. Pediatric bronchiectasis: No longer an orphan disease. Pediatr Pulmonol 2016; 51:450.</a></li><li><a class="nounderline abstract_t">Advani S, Sengupta A, Forman M, et al. Detecting respiratory viruses in asymptomatic children. Pediatr Infect Dis J 2012; 31:1221.</a></li><li><a class="nounderline abstract_t">Walker GJ, Stelzer-Braid S, Shorter C, et al. Viruses associated with acute respiratory infection in a community-based cohort of healthy New Zealand children. J Med Virol 2022; 94:454.</a></li><li><a class="nounderline abstract_t">Murray MP, Turnbull K, Macquarrie S, Hill AT. Assessing response to treatment of exacerbations of bronchiectasis in adults. Eur Respir J 2009; 33:312.</a></li><li><a class="nounderline abstract_t">Chalmers JD, Smith MP, McHugh BJ, et al. Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2012; 186:657.</a></li><li><a class="nounderline abstract_t">Hare KM, Pizzutto SJ, Chang AB, et al. Defining lower airway bacterial infection in children with chronic endobronchial disorders. Pediatr Pulmonol 2018; 53:224.</a></li><li><a class="nounderline abstract_t">Marsh RL, Thornton RB, Smith-Vaughan HC, et al. Detection of biofilm in bronchoalveolar lavage from children with non-cystic fibrosis bronchiectasis. Pediatr Pulmonol 2015; 50:284.</a></li><li><a class="nounderline abstract_t">Chang AB, Bell SC, Torzillo PJ, et al. Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand Thoracic Society of Australia and New Zealand guidelines. Med J Aust 2015; 202:21.</a></li><li><a class="nounderline abstract_t">Indinnimeo L, Tancredi G, Barreto M, et al. Effects of a program of hospital-supervised chest physical therapy on lung function tests in children with chronic respiratory disease: 1-year follow-up. Int J Immunopathol Pharmacol 2007; 20:841.</a></li><li><a class="nounderline abstract_t">Murray MP, Pentland JL, Hill AT. A randomised crossover trial of chest physiotherapy in non-cystic fibrosis bronchiectasis. Eur Respir J 2009; 34:1086.</a></li><li><a class="nounderline abstract_t">McLeese RH, O'Neill K, O'Neill B, et al. Airway clearance treatments in bronchiectasis: feasibility of linking survey results to registry data and a survey of patients' and physiotherapists' practices. ERJ Open Res 2023; 9.</a></li><li><a class="nounderline abstract_t">Joschtel B, Gomersall SR, Tweedy S, et al. Effects of exercise training on physical and psychosocial health in children with chronic respiratory disease: a systematic review and meta-analysis. BMJ Open Sport Exerc Med 2018; 4:e000409.</a></li><li><a class="nounderline abstract_t">Jones T, Baque E, O'Grady KF, et al. Barriers and facilitators of physical activity in children with bronchiectasis: Perspectives from children and parents. Front Pediatr 2022; 10:974363.</a></li><li><a class="nounderline abstract_t">Araújo D, Shteinberg M, Aliberti S, et al. The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis. Eur Respir J 2018; 51.</a></li><li><a class="nounderline abstract_t">Orriols R, Hernando R, Ferrer A, et al. Eradication Therapy against Pseudomonas aeruginosa in Non-Cystic Fibrosis Bronchiectasis. Respiration 2015; 90:299.</a></li><li><a class="nounderline abstract_t">White L, Mirrani G, Grover M, et al. Outcomes of Pseudomonas eradication therapy in patients with non-cystic fibrosis bronchiectasis. Respir Med 2012; 106:356.</a></li><li><a class="nounderline abstract_t">Blanco-Aparicio M, Saleta Canosa JL, Valiño López P, et al. Eradication of Pseudomonas aeruginosa with inhaled colistin in adults with non-cystic fibrosis bronchiectasis. Chron Respir Dis 2019; 16:1479973119872513.</a></li><li><a class="nounderline abstract_t">Chang AB, Bell SC, Byrnes CA, et al. Thoracic Society of Australia and New Zealand (TSANZ) position statement on chronic suppurative lung disease and bronchiectasis in children, adolescents and adults in Australia and New Zealand. Respirology 2023; 28:339.</a></li><li><a class="nounderline abstract_t">Valery PC, Morris PS, Byrnes CA, et al. Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial. Lancet Respir Med 2013; 1:610.</a></li><li><a class="nounderline abstract_t">Koh YY, Lee MH, Sun YH, et al. Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double-blind, placebo-controlled study. Eur Respir J 1997; 10:994.</a></li><li><a class="nounderline abstract_t">Vicendese D, Yerkovich S, Grimwood K, et al. Long-term Azithromycin in Children With Bronchiectasis Unrelated to Cystic Fibrosis: Treatment Effects Over Time. Chest 2023; 163:52.</a></li><li><a class="nounderline abstract_t">Kobbernagel HE, Buchvald FF, Haarman EG, et al. Efficacy and safety of azithromycin maintenance therapy in primary ciliary dyskinesia (BESTCILIA): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial. Lancet Respir Med 2020; 8:493.</a></li><li><a class="nounderline abstract_t">Hare KM, Grimwood K, Chang AB, et al. Nasopharyngeal carriage and macrolide resistance in Indigenous children with bronchiectasis randomized to long-term azithromycin or placebo. Eur J Clin Microbiol Infect Dis 2015; 34:2275.</a></li><li><a class="nounderline abstract_t">Kelly C, Chalmers JD, Crossingham I, et al. Macrolide antibiotics for bronchiectasis. Cochrane Database Syst Rev 2018; 3:CD012406.</a></li><li><a class="nounderline abstract_t">Tay GT, Reid DW, Bell SC. Inhaled antibiotics in Cystic Fibrosis (CF) and non-CF bronchiectasis. Semin Respir Crit Care Med 2015; 36:267.</a></li><li><a class="nounderline abstract_t">Hamworth CS, Shteinberg M, Winthrop KL, et al. RCT Abstract - The efficacy and safety of colistimethate sodium delivered via the I-neb in bronchiectasis: the PROMIS-I randomized controlled trial. Eur Respir J 2021; 58.</a></li><li><a class="nounderline abstract_t">Rubin BK. The pharmacologic approach to airway clearance: mucoactive agents. Respir Care 2002; 47:818.</a></li><li><a class="nounderline abstract_t">Nair GB, Ilowite JS. Pharmacologic agents for mucus clearance in bronchiectasis. Clin Chest Med 2012; 33:363.</a></li><li><a class="nounderline abstract_t">Anuradha KWDA, Gunathilaka PKG, Wickramasinghe VP. Effectiveness of hypertonic saline nebulization in airway clearance in children with non-cystic fibrosis bronchiectasis: A randomized control trial. Pediatr Pulmonol 2021; 56:509.</a></li><li><a class="nounderline abstract_t">Hart A, Sugumar K, Milan SJ, et al. Inhaled hyperosmolar agents for bronchiectasis. Cochrane Database Syst Rev 2014; :CD002996.</a></li><li><a class="nounderline abstract_t">Bilton D, Tino G, Barker AF, et al. Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial. Thorax 2014; 69:1073.</a></li><li><a class="nounderline abstract_t">Restrepo RD. Inhaled adrenergics and anticholinergics in obstructive lung disease: do they enhance mucociliary clearance? Respir Care 2007; 52:1159.</a></li><li><a class="nounderline abstract_t">Mortensen J, Hansen A, Falk M, et al. Reduced effect of inhaled beta 2-adrenergic agonists on lung mucociliary clearance in patients with cystic fibrosis. Chest 1993; 103:805.</a></li><li><a class="nounderline abstract_t">Shin HJ, Kim TO, Kim YI, et al. The paradoxical response to short-acting bronchodilator administration in patients with chronic obstructive pulmonary disease. J Thorac Dis 2021; 13:511.</a></li><li><a class="nounderline abstract_t">Yeh JJ, Yang YC, Hsu CY, Kao CH. Effect of Bronchodilator and Steroid Use on Heart Disease and Stroke Risks in a Bronchiectasis-Chronic Obstructive Pulmonary Disease Overlap Cohort: A Propensity Score Matching Study. Front Pharmacol 2019; 10:1409.</a></li><li><a class="nounderline abstract_t">Goyal V, Chang AB. Combination inhaled corticosteroids and long-acting beta2-agonists for children and adults with bronchiectasis. Cochrane Database Syst Rev 2014; :CD010327.</a></li><li><a class="nounderline abstract_t">Kapur N, Petsky HL, Bell S, et al. Inhaled corticosteroids for bronchiectasis. Cochrane Database Syst Rev 2018; 5:CD000996.</a></li><li><a class="nounderline abstract_t">Guran T, Ersu R, Karadag B, et al. Withdrawal of inhaled steroids in children with non-cystic fibrosis bronchiectasis. J Clin Pharm Ther 2008; 33:603.</a></li><li><a class="nounderline abstract_t">Valery PC, Torzillo PJ, Mulholland K, et al. Hospital-based case-control study of bronchiectasis in indigenous children in Central Australia. Pediatr Infect Dis J 2004; 23:902.</a></li><li><a class="nounderline abstract_t">Bastardo CM, Sonnappa S, Stanojevic S, et al. Non-cystic fibrosis bronchiectasis in childhood: longitudinal growth and lung function. Thorax 2009; 64:246.</a></li><li><a class="nounderline abstract_t">Despotes KA, Choate R, Addrizzo-Harris D, et al. Nutrition and Markers of Disease Severity in Patients With Bronchiectasis. Chronic Obstr Pulm Dis 2020; 7:390.</a></li><li><a class="nounderline abstract_t">Lee JM, Lee SA, Han CH, et al. Body mass index as a predictor of mortality in bronchiectasis: A nationwide population-based study. Respir Med 2021; 180:106370.</a></li><li><a class="nounderline abstract_t">Chalmers JD, McHugh BJ, Docherty C, et al. Vitamin-D deficiency is associated with chronic bacterial colonisation and disease severity in bronchiectasis. Thorax 2013; 68:39.</a></li><li><a class="nounderline abstract_t">Moustaki M, Loukou I, Priftis KN, Douros K. Role of vitamin D in cystic fibrosis and non-cystic fibrosis bronchiectasis. World J Clin Pediatr 2017; 6:132.</a></li><li><a class="nounderline abstract_t">Bartley J, Garrett J, Grant CC, Camargo CA Jr. Could vitamin d have a potential anti-inflammatory and anti-infective role in bronchiectasis? Curr Infect Dis Rep 2013; 15:148.</a></li><li><a class="nounderline abstract_t">Foong RE, Zosky GR. Vitamin D deficiency and the lung: disease initiator or disease modifier? Nutrients 2013; 5:2880.</a></li><li><a class="nounderline abstract_t">Binks MJ, Smith-Vaughan HC, Marsh R, et al. Cord blood vitamin D and the risk of acute lower respiratory infection in Indigenous infants in the Northern Territory. Med J Aust 2016; 204:238.</a></li><li><a class="nounderline abstract_t">Ferri S, Crimi C, Heffler E, et al. Vitamin D and disease severity in bronchiectasis. Respir Med 2019; 148:1.</a></li><li><a class="nounderline abstract_t">Epping-Jordan JE, Pruitt SD, Bengoa R, Wagner EH. Improving the quality of health care for chronic conditions. Qual Saf Health Care 2004; 13:299.</a></li><li><a class="nounderline abstract_t">Lee AL, Smith R, Burr L, et al. 'Teach me how to look after myself': What people with bronchiectasis want from education in a pulmonary rehabilitation setting. Clin Respir J 2023; 17:59.</a></li><li><a class="nounderline abstract_t">McCullough AR, Tunney MM, Quittner AL, et al. Treatment adherence and health outcomes in patients with bronchiectasis. BMC Pulm Med 2014; 14:107.</a></li><li class="breakAll">Children's Bronchiectasis Education, Advocacy and Research Network. News &amp; Resources. Available at: https://www.improvebe.org/news-resources (Accessed on September 02, 2021).</li><li><a class="nounderline abstract_t">Schutz KL, Marchant JM, Chang AB, et al. Perspective: Using Bronchiectasis Action Management Plans for Children With Bronchiectasis-Can It Improve Clinical Care? Front Pediatr 2019; 7:428.</a></li><li><a class="nounderline abstract_t">Hester KLM, Ryan V, Newton J, et al. Bronchiectasis Information and Education: a randomised, controlled feasibility trial. Trials 2020; 21:331.</a></li><li><a class="nounderline abstract_t">Sibanda D, Singleton R, Clark J, et al. Adult outcomes of childhood bronchiectasis. Int J Circumpolar Health 2020; 79:1731059.</a></li><li><a class="nounderline abstract_t">Campbell F, Biggs K, Aldiss SK, et al. Transition of care for adolescents from paediatric services to adult health services. Cochrane Database Syst Rev 2016; 4:CD009794.</a></li><li><a class="nounderline abstract_t">Moynihan KM, Ge S, Sleeper LA, et al. Life-Threatening Hemoptysis in a Pediatric Referral Center. Crit Care Med 2021; 49:e291.</a></li><li><a class="nounderline abstract_t">Charan NB, Baile EM, Paré PD. Bronchial vascular congestion and angiogenesis. Eur Respir J 1997; 10:1173.</a></li><li><a class="nounderline abstract_t">Kosar M, Kurt A, Keskin S, et al. Evaluation of effects of bronchiectasis on bronchial artery diameter with multidetector computed tomography. Acta Radiol 2014; 55:171.</a></li><li><a class="nounderline abstract_t">Polák J, Petríková J. Bronchial vascularization in patients with bronchiectasis. Radiol Clin (Basel) 1978; 47:262.</a></li><li><a class="nounderline abstract_t">Kumar A, Lodha R, Kumar P, Kabra SK. Non-cystic fibrosis bronchiectasis in children: clinical profile, etiology and outcome. Indian Pediatr 2015; 52:35.</a></li><li><a class="nounderline abstract_t">Ulutas H, Celik MR, Kuzucu A. Surgical management of upper- and lower-lobe bronchiectasis without middle lobe involvement: is middle lobectomy necessary? J Pediatr Surg 2012; 47:e25.</a></li><li><a class="nounderline abstract_t">Otgün I, Karnak I, Tanyel FC, et al. Surgical treatment of bronchiectasis in children. J Pediatr Surg 2004; 39:1532.</a></li><li><a class="nounderline abstract_t">Balci AE, Balci TA, Ozyurtan MO. Current surgical therapy for bronchiectasis: surgical results and predictive factors in 86 patients. Ann Thorac Surg 2014; 97:211.</a></li><li><a class="nounderline abstract_t">Mocelin HT, Fischer GB, Piccini JD, et al. Surgical treatment of non-cystic fibrosis bronchiectasis in children and adolescents: A review. Paediatr Respir Rev 2023; 46:57.</a></li><li><a class="nounderline abstract_t">Emiralioglu N, Dogru D, Yalcin S, et al. Impact of Surgery on Growth, Pulmonary Functions, and Acute Pulmonary Exacerbations in Children with Non-Cystic Fibrosis Bronchiectasis. Thorac Cardiovasc Surg 2019; 67:58.</a></li><li><a class="nounderline abstract_t">Fan LC, Liang S, Lu HW, et al. Efficiency and safety of surgical intervention to patients with Non-Cystic Fibrosis bronchiectasis: a meta-analysis. Sci Rep 2015; 5:17382.</a></li><li><a class="nounderline abstract_t">Kirkby S, Hayes D Jr. Pediatric lung transplantation: indications and outcomes. J Thorac Dis 2014; 6:1024.</a></li><li><a class="nounderline abstract_t">Sweet SC. Pediatric Lung Transplantation. Respir Care 2017; 62:776.</a></li><li><a class="nounderline abstract_t">Martins M, Keir HR, Chalmers JD. Endotypes in bronchiectasis: moving towards precision medicine. A narrative review. Pulmonology 2023; 29:505.</a></li><li><a class="nounderline abstract_t">Gaillard EA, Carty H, Heaf D, Smyth RL. Reversible bronchial dilatation in children: comparison of serial high-resolution computer tomography scans of the lungs. Eur J Radiol 2003; 47:215.</a></li><li><a class="nounderline abstract_t">McCallum GB, Singleton RJ, Redding GJ, et al. A decade on: Follow-up findings of indigenous children with bronchiectasis. Pediatr Pulmonol 2020; 55:975.</a></li><li><a class="nounderline abstract_t">Munro KA, Reed PW, Joyce H, et al. Do New Zealand children with non-cystic fibrosis bronchiectasis show disease progression? Pediatr Pulmonol 2011; 46:131.</a></li></ol></div><div id="topicVersionRevision">Topic 6355 Version 34.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33542057" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : European Respiratory Society guidelines for the management of children and adolescents with bronchiectasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20864608" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Bronchoarterial ratio on high-resolution CT scan of the chest in children without pulmonary pathology: need to redefine bronchial dilatation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30215382" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Bronchiectasis in children: diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29788944" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Bronchiectasis: an emerging global epidemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31475469" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Children with bronchiectasis have poorer lung function than those with cystic fibrosis and do not receive the same standard of care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19514055" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Bronchiectasis secondary to primary immunodeficiency in children: longitudinal changes in structure and function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24482322" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Chronic suppurative lung disease in a developing country: impact on child and parent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21901858" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Lower airway microbiology and cellularity in children with newly diagnosed non-CF bronchiectasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24597615" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Three clinically distinct chronic pediatric airway infections share a common core microbiota.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25111142" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Children with chronic suppurative lung disease have a reduced capacity to synthesize interferon-gamma in vitro in response to non-typeable Haemophilus influenzae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30442957" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Bronchiectasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32387516" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Pediatric Patients of Outreach Specialist Queensland Clinics Have Lung Function Improvement Comparable to That of Tertiary Pediatric Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35680151" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : International consensus statement on quality standards for managing children/adolescents with bronchiectasis from the ERS CRC Child-BEAR-Net.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31748420" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The biology of pulmonary exacerbations in bronchiectasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20173055" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Longitudinal growth and lung function in pediatric non-cystic fibrosis bronchiectasis: what influences lung function stability?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31409413" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Health-resource use and quality of life in children with bronchiectasis: a multi-center pilot cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32358912" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Cost of hospitalization for bronchiectasis exacerbation in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34291113" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Clinical and research priorities for children and young people with bronchiectasis: an international roadmap.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21830316" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Defining pulmonary exacerbation in children with non-cystic fibrosis bronchiectasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31427252" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Efficacy of oral amoxicillin-clavulanate or azithromycin for non-severe respiratory exacerbations in children with bronchiectasis (BEST-1): a multicentre, three-arm, double-blind, randomised placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30241722" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Amoxicillin-clavulanate versus azithromycin for respiratory exacerbations in children with bronchiectasis (BEST-2): a multicentre, double-blind, non-inferiority, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26840008" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Pediatric bronchiectasis: No longer an orphan disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22739572" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Detecting respiratory viruses in asymptomatic children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31017663" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Viruses associated with acute respiratory infection in a community-based cohort of healthy New Zealand children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18829674" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Assessing response to treatment of exacerbations of bronchiectasis in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22744718" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29265639" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Defining lower airway bacterial infection in children with chronic endobronchial disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24644254" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Detection of biofilm in bronchoalveolar lavage from children with non-cystic fibrosis bronchiectasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25588439" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand Thoracic Society of Australia and New Zealand guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18179758" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Effects of a program of hospital-supervised chest physical therapy on lung function tests in children with chronic respiratory disease: 1-year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19541717" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A randomised crossover trial of chest physiotherapy in non-cystic fibrosis bronchiectasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36949967" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Airway clearance treatments in bronchiectasis: feasibility of linking survey results to registry data and a survey of patients' and physiotherapists' practices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30305925" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Effects of exercise training on physical and psychosocial health in children with chronic respiratory disease: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36275072" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Barriers and facilitators of physical activity in children with bronchiectasis: Perspectives from children and parents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29386336" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26340658" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Eradication Therapy against Pseudomonas aeruginosa in Non-Cystic Fibrosis Bronchiectasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22204744" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Outcomes of Pseudomonas eradication therapy in patients with non-cystic fibrosis bronchiectasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31480862" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Eradication of Pseudomonas aeruginosa with inhaled colistin in adults with non-cystic fibrosis bronchiectasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36863703" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Thoracic Society of Australia and New Zealand (TSANZ) position statement on chronic suppurative lung disease and bronchiectasis in children, adolescents and adults in Australia and New Zealand.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24461664" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9163637" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36030839" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Long-term Azithromycin in Children With Bronchiectasis Unrelated to Cystic Fibrosis: Treatment Effects Over Time.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32380069" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Efficacy and safety of azithromycin maintenance therapy in primary ciliary dyskinesia (BESTCILIA): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26363637" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Nasopharyngeal carriage and macrolide resistance in Indigenous children with bronchiectasis randomized to long-term azithromycin or placebo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29543980" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Macrolide antibiotics for bronchiectasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25826593" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Inhaled antibiotics in Cystic Fibrosis (CF) and non-CF bronchiectasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : RCT Abstract - The efficacy and safety of colistimethate sodium delivered via the I-neb in bronchiectasis: the PROMIS-I randomized controlled trial</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12088552" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : The pharmacologic approach to airway clearance: mucoactive agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22640851" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Pharmacologic agents for mucus clearance in bronchiectasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33295693" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Effectiveness of hypertonic saline nebulization in airway clearance in children with non-cystic fibrosis bronchiectasis: A randomized control trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24817558" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Inhaled hyperosmolar agents for bronchiectasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25246664" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17716384" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Inhaled adrenergics and anticholinergics in obstructive lung disease: do they enhance mucociliary clearance?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8095449" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Reduced effect of inhaled beta 2-adrenergic agonists on lung mucociliary clearance in patients with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33717524" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : The paradoxical response to short-acting bronchodilator administration in patients with chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31849665" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Effect of Bronchodilator and Steroid Use on Heart Disease and Stroke Risks in a Bronchiectasis-Chronic Obstructive Pulmonary Disease Overlap Cohort: A Propensity Score Matching Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24913725" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Combination inhaled corticosteroids and long-acting beta2-agonists for children and adults with bronchiectasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29766487" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Inhaled corticosteroids for bronchiectasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19138237" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Withdrawal of inhaled steroids in children with non-cystic fibrosis bronchiectasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15602188" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Hospital-based case-control study of bronchiectasis in indigenous children in Central Australia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19052050" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Non-cystic fibrosis bronchiectasis in childhood: longitudinal growth and lung function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33108111" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Nutrition and Markers of Disease Severity in Patients With Bronchiectasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33765620" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Body mass index as a predictor of mortality in bronchiectasis: A nationwide population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23076388" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Vitamin-D deficiency is associated with chronic bacterial colonisation and disease severity in bronchiectasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28828295" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Role of vitamin D in cystic fibrosis and non-cystic fibrosis bronchiectasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23371406" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Could vitamin d have a potential anti-inflammatory and anti-infective role in bronchiectasis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23896653" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Vitamin D deficiency and the lung: disease initiator or disease modifier?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27031398" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Cord blood vitamin D and the risk of acute lower respiratory infection in Indigenous infants in the Northern Territory.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30827468" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Vitamin D and disease severity in bronchiectasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15289634" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Improving the quality of health care for chronic conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36404576" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : 'Teach me how to look after myself': What people with bronchiectasis want from education in a pulmonary rehabilitation setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24980161" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Treatment adherence and health outcomes in patients with bronchiectasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24980161" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Treatment adherence and health outcomes in patients with bronchiectasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31737587" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Perspective: Using Bronchiectasis Action Management Plans for Children With Bronchiectasis-Can It Improve Clinical Care?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32293509" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Bronchiectasis Information and Education: a randomised, controlled feasibility trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32090714" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Adult outcomes of childhood bronchiectasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27128768" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Transition of care for adolescents from paediatric services to adult health services.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33405412" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Life-Threatening Hemoptysis in a Pediatric Referral Center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9163664" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Bronchial vascular congestion and angiogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23897305" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Evaluation of effects of bronchiectasis on bronchial artery diameter with multidetector computed tomography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/684193" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Bronchial vascularization in patients with bronchiectasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25638182" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Non-cystic fibrosis bronchiectasis in children: clinical profile, etiology and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22424373" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Surgical management of upper- and lower-lobe bronchiectasis without middle lobe involvement: is middle lobectomy necessary?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15486899" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Surgical treatment of bronchiectasis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24200402" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Current surgical therapy for bronchiectasis: surgical results and predictive factors in 86 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36528553" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Surgical treatment of non-cystic fibrosis bronchiectasis in children and adolescents: A review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29232734" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Impact of Surgery on Growth, Pulmonary Functions, and Acute Pulmonary Exacerbations in Children with Non-Cystic Fibrosis Bronchiectasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26627202" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Efficiency and safety of surgical intervention to patients with Non-Cystic Fibrosis bronchiectasis: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25132969" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Pediatric lung transplantation: indications and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28546378" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Pediatric Lung Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37030997" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Endotypes in bronchiectasis: moving towards precision medicine. A narrative review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12927665" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Reversible bronchial dilatation in children: comparison of serial high-resolution computer tomography scans of the lungs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32096916" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : A decade on: Follow-up findings of indigenous children with bronchiectasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20717910" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Do New Zealand children with non-cystic fibrosis bronchiectasis show disease progression?</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
